文献速递头颈外科

立体定向体部放疗用于未放疗过的黏膜头颈鳞癌

Stereotactic Body Radiotherapy (SBRT) of Previously Unirradiated Mucosal Head and Neck Squamous Cell Carcinoma (SCC).
PubMed 文献 · Head Neck · 2026-06-29

回顾性分析2011至2022年74例未接受过放疗的原发黏膜头颈鳞癌患者,因不适合常规放疗而接受SBRT。中位年龄81岁,85%为ECOG 2-3,64%为T3-4期。84%获得症状缓解,1年局部控制率81%,但急性3级以上毒性36%,晚期3级以上毒性10%。

要点

  • SBRT对不适合常规放疗的老年黏膜头颈鳞癌患者可获得84%的症状缓解和81%的1年局部控制。
  • 急性3级以上毒性发生率为36%,主要为黏膜炎(30%);晚期3级以上毒性为10%。
  • PTV>159 cm³与晚期3级以上毒性显著相关(OR=15.98;p=0.0041)。

核心结论

  • 高剂量SBRT可能为不适合常规放疗的原发黏膜头颈鳞癌患者提供较高的局部控制率和姑息效果。
  • 仍需前瞻性、对照性高质量数据验证,一项比较SBRT与常规姑息放疗的随机试验(NCT06641791)正在进行。

研究设计与样本

  • 回顾性分析2011至2022年接受SBRT的既往未放疗的原发黏膜头颈鳞癌患者。
  • 共74例患者(中位年龄81岁,范围52-97;85%为ECOG 2-3),77个原发肿瘤(62%位于口腔;64%为T3-4期)。

主要发现

  • 处方为五次分割,总剂量35至50 Gy(95%接受≥40 Gy,59.7%接受≥45 Gy),每周两次;81%在14天内完成治疗,全部患者完成治疗。
  • 84%获得症状缓解,其中27.3%为完全症状缓解。
  • 中位随访7.3个月,1年局部控制率81%,区域复发率16%,远处转移率12%。
  • 中位无进展生存期和总生存期分别为6.4个月和8个月。
  • 急性3级以上毒性发生率为36%,主要为黏膜炎(30%);晚期3级以上毒性为10%(n=7),包括5例骨放射性坏死;5%(n=4)存在残留或合并疾病。

关键数值与推荐

  • SBRT处方为五次分割,总剂量35至50 Gy,每周两次。
  • PTV>159 cm³与晚期3级以上毒性显著相关(OR=15.98;p=0.0041)。

临床怎么用

  • 对于不适合常规放疗的老年黏膜头颈鳞癌患者,可考虑SBRT作为姑息治疗选择。
  • 治疗前应关注PTV体积,PTV>159 cm³时晚期3级以上毒性风险显著增加。
  • 需密切监测急性黏膜炎和晚期骨放射性坏死等毒性。

局限性

  • 回顾性研究设计,样本量有限(74例),随访时间较短(中位7.3个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) in previously untreated primary mucosal head and neck cancer (HNC) patients unfit for conventional radiation therapy. MATERIALS AND METHODS: Retrospective analysis of previously unirradiated primary SCC mucosal HNC patients treated with SBRT from 2011 to 2022. RESULTS: HN SBRT was prescribed to 74 patients (median age: 81 years [52-97]; 85% ECOG 2-3) with 77 primary tumors (62% oral cavity; 64% T3-4 disease). A five-fraction prescription ranging from 35 to 50 Gy (95% received ≥ 40 Gy, 59.7% received ≥ 45 Gy) was delivered twice weekly, with the majority (81%) completing treatment within 14 days and all patients completing treatment. Symptomatic relief was achieved by 84%, including 27.3% with complete symptomatic response. With a median follow-up of 7.3 months, 1-year outcomes were 81% local control, 16% regional recurrence rate, and 12% distant metastasis rate. Median progression-free and overall survival were 6.4 and 8 months, respectively. Acute Grade 3+ toxicity occurred in 36%, primarily mucositis (30%). Late Grade ≥ 3 toxicity was observed in 10% (n = 7), including osteoradionecrosis in 5 patients, with residual or concurrent disease present in 5% (n = 4). PTV > 159 cm3 was significantly correlated with late grade ≥ 3 toxicity (OR = 15.98; p = 0.0041). CONCLUSION: High-dose SBRT may deliver high rates of local control and palliation for primary mucosal HNC patients unfit for conventional radiation, but prospective, comparative, high-quality data are needed. A randomized trial (NCT06641791) comparing SBRT to conventional palliative RT in the elderly unfit HNC patient is underway.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Aldohan M, Karam I, Safavi AH, et al. Stereotactic Body Radiotherapy (SBRT) of Previously Unirradiated Mucosal Head and Neck Squamous Cell Carcinoma (SCC). Head Neck. 2026. PMID: 42374609. doi:10.1002/hed.70360

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。